INmune Bio reported a third-quarter loss of $0.17 per share, compared with a $0.24 loss a year earlier. That works out to 29.2% year-over-year earnings growth. The company again recorded no revenue, and no consensus estimate was available for comparison. The narrower loss is real, but it is not the story. Ebstrocel's regulatory calendar slipped again, the XPro program was effectively parked, and the company returned to the equity market at a modest price. That is the central tension: the income statement is improving while the timeline and financing picture keep getting harder.

The quality of the improvement deserves scrutiny. Net loss fell to $4.7 million from $6.5 million. R&D dropped to $3.2 million from $4.9 million, and G&A dropped to $1.8 million from $2.5 million. The year-over-year comparison flatters the trend, though. Third-quarter R&D of $3.2 million exceeded the roughly $2.8 million recorded across the entire first half of 2026, so spending is rising sequentially as manufacturing and regulatory work intensify. Other income also fell to $0.3 million from $1.0 million.

The cash statement is more telling than the loss line. Cash declined to $16.3 million from $18.4 million at the end of the second quarter, even though the company received a $4.2 million Australian R&D rebate in July. That implies a burn of roughly $2 million per month, above the $1 million to $1.5 million monthly pace guided on the prior call. Over nine months, a $5.5 million paydown of payables absorbed much of the benefit from collected tax credits.

The call laid out a now-familiar pattern of slipping UK filing dates:

• **Q4 FY25 call:** submission targeted by mid-to-late summer 2026.
• **Q2 FY26 call:** submission moved to end of Q3 or early Q4 2026.
• **Q3 FY26 call:** submission now targeted for early February 2027.

Management frames this as a strategic upgrade. It says manufacturing progress supports a complete application instead of a rolling review, which it believes could bring approval 6 to 12 weeks sooner. The expected UK approval window moved only modestly, from roughly the second quarter of 2027 to mid-2027. The U.S. timeline shifted further:

• **BLA:** pushed from the first quarter of 2027 to mid-2027 and now contingent on FDA feedback from a planned Type B meeting.
• **EMA filing:** previously targeted for early 2027, now deprioritized with no date.

XPro saw the sharpest change in framing. Last quarter, management highlighted Fast Track status and partnering for a registrational program. Now significant XPro spending is deferred until Ebstrocel is approved, replaced by an AI and quantum-computing-assisted search for a rare-disease indication. No indication has been selected.

There are genuine positives:

• **Uniphar framework:** creates a route to named-patient access in selected European, Middle Eastern and North African markets. It could generate revenue before full approval, but management gave no forecast or first-sale date, and implementation depends on country-specific arrangements.
• **Supply readiness:** commercial-scale manufacturing, Anthony Nolan cord tissue supply and Eurofins donor screening for U.S. supply are in place.
• **Confirmatory trial:** a company-funded Phase 3 is set to open in the first quarter of 2027.

However, management sized the eligible UK population at only about 100 RDEB patients, plus potential off-label use among 500 to 600 DEB patients. That frames a small initial market. The new Phase 3 also adds cost precisely when cash is tight.

Financing is where bears have legitimate ammunition. The October registered direct offering raised $4.5 million gross for 3 million shares plus 3 million warrants, or about $1.50 per share-and-warrant unit. Shares outstanding rose from 27.9 million at quarter-end to roughly 31 million, and the warrants represent further potential dilution. The raise extended guided runway from into the second quarter of 2027 to through the third quarter of 2027. That still ends around the expected UK approval window, so another financing before any meaningful revenue appears likely. Dropping the Q&A session from the call reduced transparency at a moment when investors had pointed questions.

Market data is thin this quarter, but the available reference points are not encouraging. Shares opened at $1.97 after the August report, and the 200-day moving average sits at $1.63. The October deal was priced below both levels, which suggests the stock has lost ground over the inter-earnings period. Investor sentiment and current-price data were not available.

The bottom line is that INmune Bio delivered a cleaner-looking income statement but a weaker investment setup. Cost discipline narrowed the loss, and the Uniphar deal and complete MAA strategy offer plausible paths forward. Against that, repeated timeline slippage, a burn rate above guidance, an XPro retreat and continuing dilution mean the story now rests almost entirely on Ebstrocel reaching the MHRA in February and winning approval before the cash runs short.